Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for proposed tissue/cell relaxation effects. It is grouped under the following drug class(es): Prostaglandins. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Vyzulta and Latanoprostenum Bunodum. Its PubChem CID is 11156438.
Latanoprostene bunod
| CAS No | 860005-21-6 |
|---|---|
| Molecular Formula | C27H41NO8 |
| Molecular Weight | 507.60 g/mol |
| Synonyms | 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure.
The listed CAS number is 860005-21-6.
The listed molecular formula is C27H41NO8.
The listed molecular weight is 507.60 g/mol.
4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate.
The source lists Vyzulta and Latanoprostenum Bunodum.